Lin Patrick
CIK 0001799363 Name as filed on the most recent filing
Filed as Lin Patrick (18)
20 transaction lines · from 18 filings · filed 2020-10-05 to 2026-07-01 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
20 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-30 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 2,106 acquired | 1.93 | 4,064.58 | Form 4, filing 0000897069-26-001482 | |
| 2026-06-15 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 1,831 acquired | 2.22 | 4,064.82 | Form 4, filing 0000897069-26-001408 | |
| 2026-05-29 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 1,582 acquired | 2.57 | 4,065.74 | Form 4, filing 0000897069-26-001289 | |
| 2026-05-15 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 1,369 acquired | 2.97 | 4,065.93 | Form 4, filing 0000897069-26-001182 | |
| 2026-04-30 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 1,511 acquired | 2.69 | 4,064.59 | Form 4, filing 0000897069-26-001004 | |
| 2026-04-15 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 1,369 acquired | 2.97 | 4,065.93 | Form 4, filing 0000897069-26-000908 | |
| 2026-03-31 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 1,603 acquired | 2.54 | 4,063.60 | Form 4, filing 0000897069-26-000747 | |
| 2025-01-27 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 43,500 acquired | 0.80 | 34,691.25 | Form 4, filing 0000897069-25-000130 | |
| 2024-02-01 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 1,500 acquired | 2.40 | 3,600.00 | Form 4, filing 0000897069-24-000236 | |
| 2024-01-31 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 2,500 acquired | 2.37 | 5,925.00 | Form 4, filing 0000897069-24-000236 | |
| 2022-05-17 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 2,000 acquired | 1.59 | 3,189.00 | Form 4, filing 0001567619-22-011300 | |
| 2022-04-07 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 800 acquired | 3.54 | 2,835.04 | Form 4, filing 0001567619-22-008312 | |
| 2022-04-06 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 1,200 acquired | 3.13 | 3,752.04 | Form 4, filing 0001567619-22-008312 | |
| 2021-12-14 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 3,000 acquired | 4.00 | 12,000.00 | Form 4, filing 0001567619-22-000291 | |
| 2021-12-14 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 3,000 acquired | 4.00 | 12,000.00 | Form 4, filing 0001567619-21-022195 | |
| 2021-12-03 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 3,500 acquired | 4.80 | 16,795.10 | Form 4, filing 0001567619-21-021708 | |
| 2021-08-26 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 4,000 acquired | 6.02 | 24,088.00 | Form 4, filing 0001567619-21-016470 | |
| 2021-06-21 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 2,000 acquired | 6.65 | 13,300.00 | Form 4, filing 0001567619-21-012486 | |
| 2020-10-01 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 31,250 acquired | 4.00 | 125,000.00 | Form 4, filing 0001567619-20-017589 | |
| 2020-10-01 |
Processa Pharmaceuticals, Inc. PCSA |
P, Open-market purchase | 31,250 acquired | 2.10 | 65,625.00 | Form 4, filing 0001567619-20-017572 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.
- Open-market purchase 20
- Open-market sale 0
- Option exercise 0
- Grant or award 0
- Tax withholding 0
- Disposition to the issuer 0
- In-the-money option exercise 0
How to cite this page
ebomi catalog. Lin Patrick, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001799363
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6